FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea (FRIEND)

  • STATUS
    Recruiting
  • End date
    Sep 30, 2024
  • participants needed
    200
  • sponsor
    Yale University
Updated on 7 October 2022
hysteroscopy

Summary

The objective of this study is to determine the effect of low caffeine green tea extract containing 45% epigallocatechin gallate (EGCG) on fibroids and subsequent pregnancy and live births in women seeking fertility treatment.

The population will consist of 200 women desirous of conceiving, ages ≥18 to ≤40 years (at time of consent), and known to have class 2-6 fibroids, according to the FIGO staging system.

Description

The objective of this study is to conduct a randomized double-blinded clinical trial to determine the effect of low caffeine green tea extract on fibroids and subsequent pregnancy in women seeking fertility treatment. The investigators hypothesize that EGCG in low caffeine green tea extract will reduce the fibroid size, improve the quality of endometrium, and increase the likelihood of pregnancy. To test this hypothesis, the investigators propose a randomized placebo-controlled clinical trial to evaluate live birth outcomes for women with unexplained infertility who have uterine fibroids. Participants will be randomized to either oral low caffeine green tea extract (1650mg/day) vs. placebo for up to 7 months with a 3-month run in period followed by ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 3 cycles.

Endpoints

Primary Endpoint:

  • Our primary endpoint is cumulative live birth rate.

Secondary Endpoints:

  • The conception rate.
  • The miscarriage rate.
  • The change of fibroid volume, symptom severity score, and health-related quality-of-life score, from baseline to completion of treatment, and endometrial receptivity biomarkers.
  • Time to pregnancy

This will be a randomized, multi-center, prospective, and double-blind clinical trial of low caffeine green tea extract versus placebo. Two hundred (200) participants will be randomized via computer-generated randomization schedule to receive either:

  1. low caffeine green tea extract (1650mg in 6 capsules) taken orally on a daily basis (QD) for up to 7 months (including a 3-month run in period and 1 month for every Clomiphene citrate-intrauterine insemination (CC-IUI) cycle, up to 3 cycles if no pregnancy is achieved) or
  2. matched (smell, taste, color, texture) placebo capsules taken orally on a daily basis (QD) for up to 7 months (including a 3-month run in period and 1 month for every CC-IUI cycle, up to 3 cycles if no pregnancy is achieved.

The randomization scheme will be on a 3:1 basis in favor of green tea extract, thus 150 participants will be assigned to the first arm (green tea extract) and 50 participants to the second arm (placebo).

If no spontaneous pregnancy is achieved during the run-in period and the PI decides to proceed with CC-IUI, then Clomiphene citrate will be taken for 5 days on Day 3 +/- 2 days of the participant's cycle.

Details
Condition Leiomyoma, Uterine
Treatment Placebo, Green tea extract
Clinical Study IdentifierNCT05364008
SponsorYale University
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Intramural fibroids and/or subserosal fibroids that meet the criteria for FIGO types 2-6; at least one fibroid with an average diameter of at least 1 cm in three dimensions. Participants with multiple fibroids including FIGO type 0 and type 1 will be allowed only in combination with additional fibroids type 2-6
Women ≥18 to ≤40 years of age, with six months or more infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation. Women < 35 years of age must have at least 12 months of infertility history
Baseline AMH ≥ 1.0 ng/ml
At least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography, or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the participant did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion
Minimal, mild, or moderate endometriosis (per PI discretion)
Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH ≤12 IU/L within one year prior to study initiation
Normal or corrected thyroid function within one year of study initiation
Normal prolactin level within one year of study initiation
In general, good health as assessed by PI, not taking any medications which could interfere with the study (e.g., FSH,)
Ability to have inseminations following hCG administration
If applicable, the study participant will inform their partner of trial participation
Male partner with total motile sperm in the ejaculate of at least 5 million sperm/ml, within one year of study initiation
Participant agreement to abstain from use of green tea products in any form during course of study participation in trial

Exclusion Criteria

Participants with only intracavity uterine fibroid (FIGO Type 0 or Type 1) when not in combination with other types of fibroids (FIGO type 2-6)
Currently pregnant or successful pregnancies within 6 months of initiating participation
Clinical intrauterine miscarriages prior to initiating participation: participants must wait 3 months. No exclusion for biochemical pregnancies
Subjects using Green Tea/EGCG within 2 weeks prior to study enrollment. Matcha (Japanese green tea), maca powder, green tea beverages and all other forms of green tea require a 2-week wash-out. Patients with a detectable EGCG level at the screening visit will be excluded
Undiagnosed abnormal uterine bleeding
Suspicious ovarian mass
Participants on oral contraceptives, depo-progestins, or hormonal implants (including Implanon). A two-month washout period will be required prior to screening for participants on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially when the implants are still in place. A one-month washout will be required for participants on oral cyclic progestins
Known 21-hydroxylase deficiency or other enzyme defects causing congenital adrenal hyperplasia
Type I or Type II diabetes mellitus with HbA1c > 6.5%
Known significant anemia (Hemoglobin <10 g/dL)
History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event
Known heart disease (New York Heart Association Class II or higher)
Known Liver disease (defined as AST or ALT>2 times normal, or total bilirubin >2.5 mg/dL)
Known Renal disease (defined as BUN >30 mg/dL or serum creatinine > 1.4 mg/dL)
History of, or suspected cervical carcinoma, endometrial carcinoma or breast carcinoma
History of alcohol abuse (defined as >14 drinks/week) or binge drinking of ≥ 6 drinks at one time)
Known Cushing's disease
Known or suspected adrenal or ovarian androgen secreting tumors
Allergy or contraindication to the treatment medications: EGCG, clomiphene citrate (CC) or hCG
Couples with previous sterilization procedures (e.g., vasectomy, tubal ligation) which have been reversed
Participants with untreated poorly controlled hypertension defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart
Participants who have undergone a bariatric surgery procedure in the recent past (< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon
Stage 3 and 4 endometriosis and endometriomas > 3cm
Known polycystic ovarian syndrome as evidenced by anovulation or oligoovulation hirsutism and/or elevated testosterone levels, and ovarian morphology on ultrasound examination
Donated semen
Couples in which either partner is legally married to someone else
Medical conditions that are contraindications to pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note